COX-2 inhibition: An advance or only pharmaceutical "Hype"?

Arthritis Care and Research

Volumn 45, Issue 3, 2001, Pages 209-215

  Simon, Lee S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB;

ARTHRITIS; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OSTEOARTHRITIS; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

EID: 0034790657     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200106)45:3<209::aid-art250>3.0.co;2-a     Document Type: Editorial

References (77)

1. Arthritis prevalence and activity limitations - United States, 1990
2. Clinical implications of osteoarthritis and ageing
3. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs
4. Nonsteroidal antiinflammatory drugs: Differences and similarities
5. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use
6. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: A meta-analysis
7. Gastrointestinal toxicity of the nonsteroidal antiinflammatory drugs
8. NSAIDs, gastrointestinal injury and cytoprotection
9. Nonsteroidal antiinflammatory drug gastropathy
10. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies
11. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
12. Renal complications of nonsteroidal anti-inflammatory drugs
13. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalization in Saskatchewan: A cohort study
14. Nonsteroidal antiinflammatory drugs, ulcers and risk: A collaborative meta-analysis
15. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
16. Cyclooxygenase in biology and disease
17. DO cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal antiinflammatory drugs, with less gastrointestinal toxicity?
18. Prostanoid biosynthesis and mechanisms of action
19. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
20. PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs
21. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1
22. The classification of cyclooxygenase inhibitors
23. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
24. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure
25. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: A community-based cross-sectional study
26. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population
27. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
28. Inducible cyclooxygenase may have antiinflammatory properties
29. Cyclooxygenase I contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity
30. Pharmacological analysis of cyclooxygenase-1 in inflammation
31. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
32. Limited anti-inflammatory efficacy of cyclooxygenase-2 inhibition in carrageenan-airpouch inflammation
33. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs
34. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease
35. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain
36. Distribution of COX-1 and COX-2 in normal and inflamed tissues
37. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
38. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
39. Effect of specific COX-2 inhibition in osteoarthrifts of the knee: A 6-week double-blind, placebo controlled, pilot study of rofecoxib
40. Rofecoxib, a specific inhibitor of cyclooxygenase 2 with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip
41. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized clinical trial
42. Evaluation of the functional status aspects of health related quality of life of patients with osteoarthritis treated with celecoxib
43. The anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized, controlled trial
44. Celecoxib versus diclofenac in long term management of rheumatoid arthritis: Randomized double-blind comparison
45. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
46. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on gastroduodenal mucosa of patients with osteoarthritis
47. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
48. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study, a randomized controlled trial
49. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
50. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin
51. The safety, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
52. Are selective COX-2 inhibitors nephrotoxic?
53. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
54. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line
55. Cycloxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development
56. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease
57. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis
58. A double-blind, three week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis
59. A double blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee
60. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee
61. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus 6 weeks non-steroidal anti-inflammatory drug trial
62. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance
63. Evaluation of pharmacological profile of meloxicam as an antiinflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1
64. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the Safety and Efficacy Large Scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis
65. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients: International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment
66. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state
67. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects
68. Meloxicam, 15 mg/day spares platelet function in healthy volunteers
69. Aspirin and the risk of colorectal cancer in women
70. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
71. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
72. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
73. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
74. The relationship between cyclooxygenase-2 expression and colorectal cancer
75. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells
76. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug: Independence from COX-2 protein expression
77. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases